Symptoms of anxiety and depression in patients with primary hyperhidrosis and its association with the result of clinical treatment with oxybutynin

Kamikava, Débora Yumi Ferreira; Wolosker, Nelson; Silva, Marcelo Fiorelli Alexandrino da; Campos, José Ribas Milanez de; Puech-Leão, Pedro

doi:10.6061/clinics/2021/e2892

Cited by 3 publications

(2 citation statements)

References 41 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An association and correlation between sweating and anxiety has been observed 11 . Several studies have reported that patients with hyperhidrosis are often highly anxious 12–14 .…”

Section: Introductionmentioning

confidence: 97%

“…10 An association and correlation between sweating and anxiety has been observed. 11 Several studies have reported that patients with hyperhidrosis are often highly anxious. [12][13][14] In a Brazilian cross-sectional study of 197 patients (mean age, 27.0 ± 9.3 years) who visited a medical institution, the prevalence of anxiety symptoms in patients with hyperhidrosis was 49.2% (97 of 197), almost four times higher than the 11.2% (22 of 197) for depression.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Association of primary focal hyperhidrosis with anxiety induced by sweating: A cross‐sectional study of Japanese university students focusing on the severity of hyperhidrosis and site of sweating

Ogawa

Tayama

Murota

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

Hyperhidrosis significantly reduces patients' quality of life, with many reporting feeling highly anxious. However, the relationship between hyperhidrosis and anxiety induced by sweating has not been examined in detail. The current study examined the relationship between: (1) the presence of hyperhidrosis symptoms, (2) hyperhidrosis severity, and (3) the sites of the most sweating and anxiety induced by sweating. A cross‐sectional web‐based survey was conducted among university students, and 1080 consenting participants (600 males and 480 females; mean age, 18.8 years) were included in the analysis. The survey items were: (1) diagnostic criteria for hyperhidrosis, (2) Hyperhidrosis Disease Severity Scale, (3) presence of anxiety induced by sweating, and (4) site of the most sweating. The results of multiple logistic regression analysis adjusted for sex and age showed that the odds ratio (OR) for anxiety induced by sweating was significantly higher in participants who screened positive for hyperhidrosis than in those who screened negative (OR, 9.72 [95% CI, 5.80–16.27]). The OR of anxiety induced by sweating was 7.11 (95% CI, 3.99–12.65) for mild/moderate hyperhidrosis and 23.46 (95% CI, 7.15–76.93) for severe hyperhidrosis, compared with those who screened negative for hyperhidrosis. Compared with those who screened negative for hyperhidrosis, the OR for anxiety induced by sweating in those with the palmar, plantar, axillary, and head/face as the site of the most sweating was 7.74 (95% CI, 3.91–15.33), 14.86 (95% CI, 1.83–120.58), 16.92 (95% CI, 5.95–48.14), and 5.38 (95% CI, 1.39–20.74), respectively. Our findings suggest that participants who screened positive for hyperhidrosis, mild/moderate or severe, are at a higher risk of anxiety induced by sweating than participants who screened negative for hyperhidrosis.

show abstract

“…An association and correlation between sweating and anxiety has been observed 11 . Several studies have reported that patients with hyperhidrosis are often highly anxious 12–14 .…”

Section: Introductionmentioning

confidence: 97%

mentioning

confidence: 99%

Association of primary focal hyperhidrosis with anxiety induced by sweating: A cross‐sectional study of Japanese university students focusing on the severity of hyperhidrosis and site of sweating

Ogawa

Tayama

Murota

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis

Liu

Fan

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Background Drug repurposing refers to the application of existing drugs to new therapeutic indications. As phenotypic indicators of human drug response, drug side effects may provide direct signals and unique opportunities for drug repurposing. Objectives We aimed to identify drugs frequently associated with hypohidrosis or anhidrosis adverse reactions (that is, the opposite condition of hyperhidrosis) from the pharmacovigilance database, which could be potential candidates as anti-hyperhidrosis treatment agents. Methods In this observational, retrospective, pharmacovigilance study, adverse event reports of hypohidrosis or anhidrosis in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) were assessed between January 2004 and December 2021 using reporting odds ratio (ROR) estimates and categorized by the World Health Organization Anatomical Therapeutic Chemical (ATC) classification code. The onset time of drug-associated hypohidrosis or anhidrosis was also examined. Results There were 540 reports of 192 drugs with suspected drug-associated hypohidrosis or anhidrosis in the FAERS database, of which 39 drugs were found to have statistically significant signals. Nervous system drugs were most frequently reported (187 cases, 55.82%), followed by alimentary tract and metabolism drugs (35 cases, 10.45%), genitourinary system and sex hormones (28 cases, 8.36%), and dermatologicals (22 cases, 6.57%). The top 3 drug subclasses were antiepileptics, drugs for urinary frequency and incontinence, and antidepressants. Taking disproportionality signals, pharmacological characteristics of drugs and appropriate onset time into consideration, the main putative drugs for hyperhidrosis were glycopyrronium, solifenacin, oxybutynin, and botulinum toxin type A. Other drugs, such as topiramate, zonisamide, agalsidase beta, finasteride, metformin, lamotrigine, citalopram, ciprofloxacin, bupropion, duloxetine, aripiprazole, prednisolone, and risperidone need more investigation. Conclusions Several candidate agents among hypohidrosis or anhidrosis-related drugs were identified that may be redirected for diminishing sweat production. There are affirmative data for some candidate drugs, and the remaining proposed candidate drugs without already known sweat reduction mechanisms of action should be further explored.

show abstract

DeepBiomarker2: Prediction of alcohol and substance use disorder risk in post-traumatic stress disorder patients using electronic medical records and multiple social determinants of health

Miranda

Fan

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Prediction of high-risk events amongst patients with mental disorders is critical for personalized interventions. In our previous study, we developed a deep learning-based model, DeepBiomarker by utilizing electronic medical records (EMR) to predict the outcomes of patients with suicide-related events in post-traumatic stress disorder (PTSD) patients. Methods We improved our deep learning model to develop DeepBiomarker2 through data integration of multimodal information: lab tests, medication use, diagnosis, and social determinants of health (SDoH) parameters (both individual and neighborhood level) from EMR data for outcome prediction. We further refined our contribution analysis for identifying key factors. We applied DeepBiomarker2 to analyze EMR data of 38,807 patients from University of Pittsburgh Medical Center diagnosed with PTSD to determine their risk of developing alcohol and substance use disorder (ASUD). Results DeepBiomarker2 predicted whether a PTSD patient will have a diagnosis of ASUD within the following 3 months with a c-statistic (receiver operating characteristic AUC) of 0·93. We used contribution analysis technology to identify key lab tests, medication use and diagnosis for ASUD prediction. These identified factors imply that the regulation of the energy metabolism, blood circulation, inflammation, and microbiome is involved in shaping the pathophysiological pathways promoting ASUD risks in PTSD patients. Our study found protective medications such as oxybutynin, magnesium oxide, clindamycin, cetirizine, montelukast and venlafaxine all have a potential to reduce risk of ASUDs. Discussion DeepBiomarker2 can predict ASUD risk with high accuracy and can further identify potential risk factors along with medications with beneficial effects. We believe that our approach will help in personalized interventions of PTSD for a variety of clinical scenarios.

show abstract

Symptoms of anxiety and depression in patients with primary hyperhidrosis and its association with the result of clinical treatment with oxybutynin

Cited by 3 publications

References 41 publications

Association of primary focal hyperhidrosis with anxiety induced by sweating: A cross‐sectional study of Japanese university students focusing on the severity of hyperhidrosis and site of sweating

Association of primary focal hyperhidrosis with anxiety induced by sweating: A cross‐sectional study of Japanese university students focusing on the severity of hyperhidrosis and site of sweating

Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis

DeepBiomarker2: Prediction of alcohol and substance use disorder risk in post-traumatic stress disorder patients using electronic medical records and multiple social determinants of health

Contact Info

Product

Resources

About